Food and Drug Administration (FDA) approved the pill form of Wegovy on December 22, 2025
Scheduling follow-up appointments to check HbA1c levels, typically 8-12 weeks after stopping, to assess the impact on long-term glucose control
Key limitations: Some compounds have direct human pharmacodynamic data
Changes may include looser clothing, a smaller waistline, steady week-to-week progress, and increased motivation
Individuals should always talk to their healthcare provider if they have any concerns or experience issues with their medication or injection technique
The outcome data in T1DM is very limited and more data is needed #SGLT2inhibitors #GLP1receptoragonist #SGLT2i #GLP1 #nsMRA #nonsteroidalmineralocorticoidreceptorantagonists #CVcomplications #DKD #cardioprotection #nephroprotection #combinationtherapy Martin Haluzks Post 2, 1- : Very interesting paper recently published in Diabetes Therapy by Elisabeth Buur Stougaard and colleagues